← Back to catalogue

Eluent 80cv

FDA UDI

Class II (US FDA UDI)

by Arkray Usa, Inc.

Identity

Trade Name
ELUENT 80CV FDA UDI
Generic Name
Glycated haemoglobin (HbA1c) IVD, reagent FDA UDI
Device Name
These products are used with the ADAMS A1c HA-8180 series for the determination of Hemoglobin A1c (HbA1c) in human whole blood. These products are used to elute and remove hemoglobin in the column in order of binding strength. FDA UDI
Model / Reference
103397 FDA UDI
Description
These products are used with the ADAMS A1c HA-8180 series for the determination of Hemoglobin A1c (HbA1c) in human whole blood. These products are used to elute and remove hemoglobin in the column in order of binding strength. FDA UDI

Identifiers

Primary DI / UDI-DI
04987486015116 FDA UDI
510(k) Number
K162822 FDA UDI
FDA Product Code
PDJ FDA UDI
GMDN Term
Glycated haemoglobin (HbA1c) IVD, reagent FDA UDI

Classification

Device Class
Class II FDA UDI
Regulation Number
862.1373 FDA UDI
Commercial Distribution
In Commercial Distribution FDA UDI

Clinical & Handling

Sterile

No

FDA UDI

Single Use

Yes

FDA UDI

Implantable

No

FDA UDI

Contains Latex

No

FDA UDI

Prescription Use

No

FDA UDI

Over-the-Counter

No

FDA UDI

Convenience Kit

No

FDA UDI

Combination Product

No

FDA UDI

HCT/P

No

FDA UDI

Premarket Exempt

No

FDA UDI

Lot / Batch Number

Yes

FDA UDI

Serial Number

No

FDA UDI

Expiration Date

Yes

FDA UDI

Manufacturing Date

No

FDA UDI

Category: Glycated haemoglobin (HbA1c) IVD, reagent

Eluent 80cv by Arkray Usa, Inc. — Class II — FDA UDI — listed in FDA GUDID — regulatory data on deviCERTS

Similar devices

Also classified as Glycated haemoglobin (HbA1c) IVD, reagent.

Cleared under the same submission

Authorization Coverage (1 country)

Regulatory Authorizations

United States Pending data

FDA UDI

Is this your device? Claim it to add documentation and request validation.

Manufacturer

Manufacturer
Arkray Usa, Inc.

Sources (1)

  • FDA UDI c3404dad-7e38-44a7-8104-b1b459ecdc28 36 fields · synced May 30, 2026